Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Post-Patent Cliff Tab: Pharma Battered But Still Financially Strong, Says Moody’s

This article was originally published in The Pink Sheet Daily

Executive Summary

The patent cliff has battered pharma companies’ financial underpinnings over the past three years, both directly and indirectly, but the industry is still comparatively well endowed to face new macro challenges, ranging from health care reform to pricing pressure and relentless competition, according to Moody’s.


Related Content

Biopharma M&A In An Era Of Elusive Growth, Capital Triage, and New Competitors
Ahead Of Schedule, Pfizer Prepares To Set Zoetis Free In Stock Swap
Pfizer Sells Nutrition Portfolio To Nestle For Nearly $12B


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts